In triple-negative breast cancer (TNBC), wild-type IDH2 has been identified as a crucial driver of tumor survival and proliferation, with its inhibition leading to impaired energy metabolism, reduced tumor growth, and enhanced apoptosis. Here, IDH2 is linked to triple-negative breast carcinoma.